Get the Stockscreener App
57.40
5.63%
3.06
After Hours:
57.75
0.35
+0.61%
Nektar Therapeutics stock is traded at $57.40, with a volume of 478.88K.
It is up +5.63% in the last 24 hours and up +17.91% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$54.34
Open:
$55.3
24h Volume:
478.88K
Relative Volume:
0.51
Market Cap:
$1.09B
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-39.32
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-4.22%
1M Performance:
+17.91%
6M Performance:
+9,193%
1Y Performance:
+4,121%
1-Day Range:
$54.12
$57.87
1-Week Range:
$52.91
$60.40
52-Week Range:
$0.432
$62.95
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
57.40 | 1.03B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) - Yahoo Finance
Nektar Therapeutics (NKTR): Assessing Valuation After a Strong Multi-Month Share Price Rally - Yahoo Finance
Why retail investors pile into Nektar Therapeutics stockWeekly Investment Report & Verified Stock Trade Ideas - newser.com
Is Nektar Therapeutics stock a good choice for value investorsGap Up & Verified Entry Point Signals - newser.com
Best data tools to analyze Nektar Therapeutics stockJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Using economic indicators to assess Nektar Therapeutics potentialJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street - The Globe and Mail
Will Nektar Therapeutics stock benefit from AI adoptionEarnings Risk Report & AI Forecast Swing Trade Picks - newser.com
Custom strategy builders for tracking Nektar TherapeuticsVolume Spike & Expert Curated Trade Setups - newser.com
Quantitative breakdown of Nektar Therapeutics recent moveQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September - MSN
Wealth Enhancement Advisory Services LLC Reduces Stake in Nektar Therapeutics $NKTR - MarketBeat
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today - MSN
Nektar Therapeutics' (NKTR) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
What MACD and RSI say about Nektar TherapeuticsJuly 2025 Fed Impact & Smart Money Movement Tracker - newser.com
Evaluating Nektar Therapeutics with trendline analysisJuly 2025 Breakouts & Free Reliable Trade Execution Plans - newser.com
Moderate to Severe Atopic Dermatitis Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - The Globe and Mail
How Nektar Therapeutics (ITH0) stock responds to job market shiftsNew Guidance & Reliable Price Breakout Alerts - newser.com
Sector ETF performance correlation with Nektar Therapeutics2025 Technical Patterns & AI Driven Price Predictions - newser.com
Gainplan LLC Buys New Shares in Nektar Therapeutics $NKTR - MarketBeat
Public Employees Retirement System of Ohio Sells 121,001 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NKTR): Examining Valuation After Breakthrough Eczema Drug Trial Results Spark Investor Interest - Sahm
How Nektar Therapeutics (ITH0) stock reacts to weak economyDividend Hike & Real-Time Stock Movement Alerts - newser.com
What analysts say about Nektar Therapeutics stockSwing Trading Watchlist & Build Wealth With Expert Timing Advice - earlytimes.in
Real time social sentiment graph for Nektar TherapeuticsTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Is a relief rally coming for Nektar Therapeutics holdersTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How analysts rate Nektar Therapeutics stock today2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Why Nektar Therapeutics (NKTR) Is Up 8.8% After Positive Phase 2b Rezpegaldesleukin Data at EADV - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 61.24 USD By Investing.com - Investing.com South Africa
Nektar Therapeutics stock hits 52-week high at 61.24 USD - Investing.com
The biotech scorecard for the fourth quarter: 36 stock-moving events to watch - statnews.com
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
Building trade automation scripts for Nektar TherapeuticsJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
Voya Investment Management LLC Raises Stock Holdings in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):